M. Reck

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D. Planchard, T. Mok, P. V. Van Schil, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. G. Levra, Johan Vansteenkiste, Sanne A.E. Peters, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Senan, K. Kerr, S. Novello, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration.

S. Novello, J. Vansteenkiste, T. Čufer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. G. Levra, Johan Vansteenkiste, Sanne A.E. Peters, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

R. Kowalyszyn, L. Paz-Ares, T. Ciuleanu, 2023, ESMO open.